

Supporting Information

Table of contents

A	SI Materials and Methods.....	2
B	Fig. S1. Gating strategy.....	8
C	Fig. S2. Clonotype sharing of gluten-specific CD4 ⁺ T cells across anatomical compartments and within the same sample.....	9
D	Fig. S3. Clonal distribution and diversity in CD patients.....	10
E	Fig. S4. Pre-existing T-cell clonotypes dominate during gluten challenge.....	11
F	Fig. S5. Identical secondary TCR α chain in persisting clonotypes	12
G	Fig. S6. Expanded T-cell clonotypes persist in gut tissue and blood over decades.....	13
H	Table S1. Clinical features of patients included in the study.....	14
I	Table S2. List of CDR3 amino acid sequences of public TCR sequences.....	16
J	Table S3. List of CDR3 nucleotide sequences of paired public TCR sequences.....	20

SI materials and Methods

Single-cell TCR sequencing using multiplex PCR

To obtain paired TCR α and TCR β sequences, we performed PCR with multiplexed primers covering all TCR α and TCR β V genes according to the published protocol (1). However, different from the protocol published by Han et al, we performed cDNA synthesis and the first PCR reaction in two separate steps. We sorted single cells into 96-well plates containing 5 μ l capture buffer (20 mM Tris-HCl pH8, 1% NP-40, 1 U/ μ l RNase Inhibitor (optional)). The plates were stored at -70°C until cDNA synthesis to facilitate cell lysis. For cDNA synthesis, we added 5 μ l cDNA mix (1X FS buffer, 1 mM dNTP, 2.5 mM DDT, 1 μ M oligo d(T) (5'-CTGAATTCT₍₁₆₎-3'), 1 μ M reverse *TRAC* (5'-AGTCAGATTGTTGCTCCAGGCC-3') and *TRBC* (5'-TTCACCCACCAGCTCAGCTCC-3') primers, 1.5 U/ μ l RNase Inhibitor, 2.5 U/ μ l Superscript II in final 10 μ l reaction volume). The cDNA synthesis was carried out at 42°C for 50 min followed by an inactivation step at 72°C for 10 min. The cDNA plates were stored at -20°C. Each of the three nested PCR steps was carried out in a total volume of 10 μ l using 1 μ l cDNA/PCR template and KAPA HiFi HotStart ReadyMix (Kapa Biosystems). For the two first nested PCR reactions, the final concentration of each TCR V-gene and C-gene primers was 0.06 μ M and 0.3 μ M, respectively. In the final barcoding PCR step, we added 5'-barcoding primers (0.044 μ M) and 1:4 ratio of the 3'-barcoding primers, *TRBC* (0.044 μ M) and *TRAC* (0.18 μ M). In addition, Illumina Paired-End primers were added to the master mix (0.5 μ M each). Primer sequences and cycling conditions for all three PCR reactions are provided in the original protocol (1).

Bulk TCR sequencing by PCR amplification of template-switched cDNA

When feasible due to high cell numbers, we sorted in bulk 150-3000 T cells in an eppendorf tube containing 50-100 μ l TCL lysis buffer (Qiagen) supplemented with 1% β -mercaptoethanol. We stored the tubes at -70°C until cDNA synthesis. Total RNA was extracted by incubation with 2.2x volume of RNAclean XP beads (Agencourt) for 10 min at room temperature before tubes were placed on a magnet (DynaMag-2, Invitrogen) and washed three times with 80% ethanol. We allowed the beads to dry while still on magnet and eluted in H₂O. A modified SMART protocol (2) was used in first-strand cDNA synthesis. The eluted RNA was transferred to

RT1 mix (20 mM Tris-HCl pH 8, 0.2% Tween-20, 1 mM dNTP, 2 µM oligo d(T), 1 U/µl RNase Inhibitor) in total volume of 20 µl and incubated at 72°C for 3 min followed by 1 min on ice. To complete cDNA synthesis, we added equal volume of the RT2 mix (1X FS buffer, 0.8 M Betaine, 6 mM MgCl₂, 2.5 mM DTT, 2 µM TSO (5'-Bio-AAGCAGTGGTATCAACGCAGAGTACrGrGrG-3'), 1 U/µl RNase Inhibitor, 10 U/µl SuperScript II). The cDNA synthesis was carried out at 42°C for 90 min followed by 15 min at 72°C. Subsequently, *TRA* and *TRB* genes were amplified in two rounds of semi-nested PCR reactions. The cDNA from each sample was divided into 3-6 replica and amplified with indexed primers. The reaction mix for the first PCR: 2 µl cDNA template, 200/40 nM forward primer mix (STRT-fwd S/L), 200 nM reverse primer (TRAC_rev1 or TRBC_rev1) with KAPA HiFi HotStart ReadyMix in a total volume of 20 µl was amplified by touchdown PCR to increase specificity. The cycling conditions were: 3 min at 95°C followed by 5 cycles (15s x 98°C, 60s x 72°C), 5 cycles (15s x 98°C, 30s x 70°C, 40s x 72°C) and 8 cycles (15s x 98°C, 30s x 65°C, 40s x 72°C). The second PCR was done in a total volume of 10 µl with 1 µl of first PCR product, 200 nM indexed forward primers (R2_STRT_In01-12), 200 nM barcoded reverse primers (*TRAC_01-10_rev2* or *TRBC_01-10_rev2*) and KAPA HiFi HotStart ReadyMix for 2 min at 95°C followed by 10 cycles (20s x 98°C, 30s x 65°C, 40s x 72°C) with final elongation at 72°C for 5 min. A final third PCR reaction was carried out in a total volume of 20 µl with 2 µl of second PCR product, 200 nM forward primer (Illumina Seq Primer R2), 200 nM reverse primer (Illumina Seq Primer R1) and KAPA HiFi HotStart ReadyMix to prepare the sequencing library for the Illumina MiSeq platform. The cycling conditions were: 2 min at 95°C followed by 15 cycles (20s x 98°C, 30s x 60°C, 40s x 72°C) with final elongation at 72°C for 5 min. The PCR products were pooled, cleaned and concentrated with Ampure XP beads (Agencourt) or QIAquick PCR purification kit prior to gel extraction and cleaned with QIAquick Gel Extraction kit and QIAquick PCR purification kit (Qiagen). All primer sequences are listed below:

Oligo	Barcode	Sequence (5'-3')
1st PCR		
fwdS		Bio-CTAATACGACTCACTATAAGGC
fwdL		Bio-CTAATACGACTCACTATAAGGGCAAGCAGTGGTATCAACGCAGAGT
TRAC_rev1		GGAACTTCTGGCTGGGAAGAAGGTGTCTCTGG
TRBC_rev1		TGCTTCTGATGGCTCAAACACAGCGACCT
2nd PCR fwd Replica barcode		
R2_bulk01	ATGAGC	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNATGAGCAAGCAGTGGTATCAACGCAGAGT
R2_bulk02	CAACTA	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNCAACTAAAGCAGTGGTATCAACGCAGAGT
R2_bulk03	CTAGCT	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNTAGCTAACGAGTGGTATCAACGCAGAGT
R2_bulk04	ACTTGA	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNACTGAAAGCAGTGGTATCAACGCAGAGT
R2_bulk05	CACTCA	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNCACTCAAAGCAGTGGTATCAACGCAGAGT
R2_bulk06	TACAGC	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNTACAGCAAGCAGTGGTATCAACGCAGAGT
R2_bulk07	CGTGAT	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNCGTATAAGCAGTGGTATCAACGCAGAGT
R2_bulk08	CACTGT	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNCACTGTAAGCAGTGGTATCAACGCAGAGT
R2_bulk09	TGGTCA	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNGGTCAAAGCAGTGGTATCAACGCAGAGT
R2_bulk10	ATTGGC	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNATTGGCAAGCAGTGGTATCAACGCAGAGT
R2_bulk11	TACAAG	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNTACAAGAAGCAGTGGTATCAACGCAGAGT
R2_bulk12	GGAACT	GGCATT CCTGCTGAACC GCTCTCCGATCTNNNNNNNGAACTAACGAGTGGTATCAACGCAGAGT
2nd PCR rev Sample barcode		
TRAC01_rev2	ACCGTA	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNACCGTACAGCTGGTACACGGCAGGGT
TRAC02_rev2	GAGTAG	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNAGTAGCAGCTGGTACACGGCAGGGT
TRAC03_rev2	TTACGC	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNTACGCCAGCTGGTACACGGCAGGGT
TRAC04_rev2	CGTACT	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNCGTACTCAGCTGGTACACGGCAGGGT
TRAC05_rev2	GTGAAA	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNGTAAACAGCTGGTACACGGCAGGGT
TRAC06_rev2	TAGCTT	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNTAGCTCAGCTGGTACACGGCAGGGT
TRAC07_rev2	ACTGAT	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNACTGATCAGCTGGTACACGGCAGGGT
TRAC08_rev2	CCGTCC	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNCGTCCCAGCTGGTACACGGCAGGGT
TRAC09_rev2	GGCTAC	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNGCTACCAGCTGGTACACGGCAGGGT
TRAC10_rev2	ATT CCT	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNATT CCTCAGCTGGTACACGGCAGGGT
TRBC01_rev2	ATCTCG	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNATCTCGGACCTCGGTGGAACAC
TRBC02_rev2	CAGATC	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNCAGATCCGACCTCGGTGGAACAC
TRBC03_rev2	TGACGA	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNTGACGACGACCTCGGTGGAACAC
TRBC04_rev2	GCTGAT	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNGCTGATCGACCTCGGTGGAACAC
TRBC05_rev2	CGATGT	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNCGATGTCGACCTCGGTGGAACAC
TRBC06_rev2	ACCACA	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNACCACACGACCTCGGTGGAACAC
TRBC07_rev2	GATCAG	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNGATCAGCGACCTCGGTGGAACAC
TRBC08_rev2	TCGGTC	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNTCGGTCCGACCTCGGTGGAACAC
TRBC09_rev2	GTCTGC	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNNGTCTGCCGACCTCGGTGGAACAC
TRBC10_rev2	AGTCAA	ACACTTTCCCTACACGACGCTCTCCGATCTNNNNNNAGTCAACGACCTCGGTGGAACAC
3rd PCR		
R1		AATGATA CGGC GACC ACCGAG ATCTAC ACTCTT CCCTACACGACGCTCTCCGATC
R2		CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATT CCTGCTGAACCGCTC

The sequencing was done at Norwegian Sequencing Centre (NSC), a core facility at the University of Oslo and Oslo University Hospital.

Data processing and analysis

Raw reads from Illumina NGS were processed in a multistep pipeline. Single-cell TCR sequencing data was first pre-processed by using selected steps of the pRESTO toolkit (3). First, low-quality reads with average Phred quality score Q<30 were removed. Sequences were then unmasked according to barcodes (row, plate and column) and gene-specific primers (TRA/TRB), which were then annotated in the read header. Reads without recognizable primer sequences were removed. Subsequently, forward (R2) and reverse (R1) reads were paired according to Illumina coordinates and assembled into full-length TCR sequences. Next, identical duplicate sequences derived from the same cell were collapsed and the number of sequences collapsing as one sequence was denoted as “dupcount”. Only sequences with dupcount > 2 were used for further analysis. In the last pre-processing step, we aligned the three highest ranking (in terms of dupcount) sequences on a per-cell, per-chain basis, implemented as a custom python script. Here, the highest-ranking sequence was aligned to the second highest ranking sequence using a dynamic programming algorithm (4). For sequences aligning with < 2% mismatches (relative to the length of the highest-ranking sequence, and ignoring gaps), the highest-ranking sequence was retained and the dupcounts were added up. Remaining sequences were discarded. Subsequently, the third-highest ranking sequence was aligned to the previous outcome, and possibly merged as well. Other pairs of the top three sequences were aligned as needed, always prioritizing the highest-ranking sequence in terms of dupcounts.

Bulk-cell derived sequencing data was pre-processed in much of the same manner as pre-processing of single-cell sequencing data described above. The difference was that sequences were marked according to barcoded gene-specific primers (TRA/TRB) in the R1 reads and the TSO sequence together with replicate barcodes in the R2 reads. The barcoded primers were then annotated in the read header.

We submitted pre-processed TCR sequences to the IMGT/HighV-QUEST online tool (5) for identification of V, D, J genes and alleles and the nucleotide sequences of the CDR3 junctions. Before analyzing the IMGT/HighV-QUEST output, the IMGT annotation was parsed, stored in a relational database and subjected

to additional filters before extracting the sequences. This workflow was implemented as an in-house Java program together with a custom MySQL database. First, only productive sequences according IMGT annotation was included. For single-cell data, within each cell and each chain, duplicate sequences that had identical V gene, J gene and nucleotide CDR3 sequences were collapsed. Next, only valid singleton cells containing single TRA and TRB and dual TRA or TRB (maximum 3 chains) with dupcount > 100 were considered for downstream analysis. Within samples taken from the same individual, cells were defined to belong to the same clonotype when they share identical V and J gene (subgroup level) in addition to identical nucleotide CDR3 region for both the TRA and TRB genes. All bulk samples were divided after cDNA synthesis and amplified in independent PCR reactions that were barcoded with 3-6 replicate indices. Within each bulk TCR sample replicate, duplicate sequences defined as identical V gene, J gene and allowing for one nucleotide mismatch in CDR3 regions to account for PCR and sequencing errors were collapsed. Only sequences present in ≥ 2 distinct replicas and cumulative dupcount > 10 were used for downstream analysis.

Area-proportional Venn diagrams were drawn by using free software available from Bioinforx (<http://apps.bioinforx.com>) and eulerAPE (6).

References

1. Han A, Glanville J, Hansmann L, Davis MM. Linking T-cell receptor sequence to functional phenotype at the single-cell level. *Nat Biotechnol.* 2014;32(7):684-692.
2. Quigley MF, Almeida JR, Price DA, Douek DC. Unbiased molecular analysis of T cell receptor expression using template-switch anchored RT-PCR. *Curr Protoc Immunol.* 2011;Chapter 10:Unit10 33.
3. Vander Heiden JA, Yaari G, Uduman M, et al. pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. *Bioinformatics.* 2014;30(13):1930-1932.
4. Needleman SB, Wunsch CD. A general method applicable to the search for similarities in the amino acid sequence of two proteins. *J Mol Biol.* 1970;48(3):443-453.
5. Alamyar E, Duroux P, Lefranc MP, Giudicelli V. IMGT((R)) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. *Methods Mol Biol.* 2012;882:569-604.
6. Micallef L, Rodgers P. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. *PLoS One.* 2014;9(7):e101717.

Fig. S1: Gating strategy. For PBMCs, cells within the singlet lymphocyte population were further gated to isolate tetramer-binding CD4⁺ effector-memory gut-homing T cells that were: CD3⁺, CD11c⁻, CD14⁻, CD15⁻, CD19⁻, CD56⁻, CD45RA⁻, CD62L⁻, integrin β7⁺ and CD4⁺. For lamina propria cell suspensions of duodenal biopsies, live cells within the singlet lymphocyte population were further gated to obtain tetramer-binding CD4⁺ T cells that were: CD3⁺, CD11c⁻, CD14⁻, CD15⁻, CD19⁻, CD56⁻, CD8⁻ and CD4⁺. For T-cell lines, live cells within the singlet lymphocyte population were further gated to obtain tetramer-binding CD4⁺ T cells that were: CD3⁺, CD8⁻ and CD4⁺.




Fig. S2: Clonotype sharing of gluten-specific CD4⁺ T cells across anatomical compartments and within the same sample. Panel A shows clonotype sharing of HLA-DQ:gluten tetramer-sorted cells from matched blood and gut biopsy samples of untreated CD patients that were subjected to bulk TCR β sequencing. TCR β clonotype is defined by nucleotide sequence and the overlap is depicted in area-proportional Venn diagrams. Degree of sharing was calculated by dividing the number of shared clonotypes by the total clonotype number in the blood sample. Panel B shows the range of maximum expected clonotype overlap between two independent sequencing experiments (single-cell and bulk TCR sequencing) of the same sample. Percentages of TCR β clonotype overlap was calculated by dividing the number of shared clonotypes by the total clonotype number in the smallest sample. Median is depicted as a line and 95% confidence interval is depicted as stippled lines.




Fig. S3. Clonal distribution and diversity in CD patients. Panel A shows clonal distribution of TCR $\alpha\beta$ clonotypes obtained by single-cell TCR sequencing of gluten-specific T cells from four CD patients during the first weeks (w) and 1-2 years (yr) after commencement of gluten-free diet (GFD). Panel B shows clonal diversity as sample-corrected non-parametric estimate of the classic Shannon entropy in samples with >20 cells of the patients represented in Fig 1. Panel C shows clonal distribution of TCR $\alpha\beta$ clonotypes obtained by single-cell TCR sequencing of gluten-specific T cells from five CD patients during 14-day gluten challenge; at baseline (B), on day 6 (D6), day 14 (D14) and day 28 (D28) after the onset of gluten challenge. Panel D shows clonal diversity as sample-corrected non-parametric estimate of the classic Shannon entropy in samples with >20 cells of the patients represented in Fig 2. Panels A and C show the distribution of clonotypes consisting of at least two cells plotted as stacked boxes in percentage of total number of cells. The clonal size of the most dominant clonotype is displayed with number inside the box. The total number of clonotypes and cells in each sample are shown below each stacked bar. For panel C, the colored boxes represent the three most dominant clonotypes at D6 that were also observed at other time points. The isolated and non-stacked colored boxes represent shared clonotypes with clonal size one.




Fig. S4. Pre-existing T-cell clonotypes dominate during gluten challenge. TCR $\alpha\beta$ clonotypes obtained by single-cell sequencing at baseline, day 6 and day 14 or day 28 of the gluten challenge were analyzed and compared in area-proportional Venn diagrams (A). The dark red areas represent clonotypes that were observed both at baseline and day 6 or day 14 or day 28. The percentage denotes the proportion of these shared clonotypes on day 6 (purple) or day 14 (blue) or day 28 (orange). Panel B shows overlap of TCR β clonotypes at baseline, day 6 and day 14 or day 28 of the gluten challenge in patients CD442 and CD1300. The percentage in blue color denotes the proportion of shared clonotypes in the latest sample while purple color denotes the proportion of shared clonotypes in the earliest sample. The TCR β clonotypes were obtained from compilation of both single-cell and bulk sequencing data and corresponds to panel D in Figure 4.





Fig S5. Identical secondary TCR α chain in persisting clonotypes. Representative persisting gluten-specific TCR clonotypes that have identical secondary productive TCR α chains are shown. The number of circles represents the number of cells and each line represents the TCR α and TCR β sequences used in the cell. The *TRAV/TRBV*, CDR3 α /CDR3 β (nucleotide) and *TRAJ/TRBJ* usage in the respective TCR α and TCR β sequences are shown.

CD114



CD1283



CD1268




Fig. S6. Expanded T-cell clonotypes persist in gut tissue and blood over decades. Panel A shows sharing of TCR $\alpha\beta$ clonotypes from in vitro expanded T-cell lines (TCL) from one single biopsy specimen and blood/gut samples of CD patients obtained 16-20 years apart. The overlap is depicted in area-proportional Venn diagrams and degree of overlap is calculated by dividing the number of shared clonotypes by the total number of clonotypes in the most recent samples. Panel B shows the fraction (%) of cells belonging to the shared clonotypes in the most recent samples. The total number of cells is depicted in the center of the pie charts.




Table S1. Clinical features of patients included in the study

Patient ID ^a	HLA-DQ2/8	Year of birth	Year of diagnosis	Gluten status ^b	Marsh Score ^c	IgA-TG2 ^d	IgG-DGP ^e	# Tetr+ T cells in gut ^f	# Tetr+ T cells in blood ^g	Sequencing library ^h
CD1228 (m)	2.5	1982	2013	UCD	3c	8.7	11	13400	-	bulkLib2
CD1308 (m)	2.5	1973	2015	UCD	3a	5.3	29	10300	16.9	bulkLib2
CD1317 (m)	2.5	1969	2015	UCD	3c	78.8	>100	9000	27.7	bulkLib2
CD1375 (m)	2.5	1975	2016	UCD 4w GFD 10w GFD	3a - -	41.7 9.1 5.1	14 9 6.9	24700 - -	70.9 21.8 9.6	scLib3 scLib4
CD1374 (f)	8	1992	2016	UCD 4w GFD 10w GFD	3c - -	32 17.6 10.0	54 39 25	5100 - -	2.5 1.4 0.9	scLib4
CD1368 (m)	2.5	1972	2015	UCD 10w GFD 16w GFD 1yr GFD	3c - - 2	18 3.8 2.8 <1	>100 - 90.8 17	7200 - - 3400	8.4 9.8 10.4 4.7	scLib4 scLib6
CD1237 (m)	2.5	1961	2013	UCD 1yr GFD	3b 0	3.1 <1	16 <5	9400 2400	8.5 0.5	scLib2
CD1283 (f)	2.5	1966	2014	UCD 1yr GFD 2yr GFD	3b 3a 3a-b	27.3 4.0 1.3	>100 39 17	- 4800 2300	12.7 6.7 3.3	scLib4 scLib6
CD1268 (m)	2.5	1991	2014	UCD 1yr GFD 2yr GFD	3b-c 3a-b 1-2	14.0 <1 1.2	>100 16 10	- 3800 2900	34.0 71.7 10.7	scLib4 scLib6
CD442 (m)	2.5	1958	2000	Baseline Day 6 Day 14	3 - 3	2.3 2.2 3.1	8 9 10	22200 - 22800	46.8 260.6 183.2	scLib2/3, bulkLib3
CD1300 (f)	2.5	1954	1987	Baseline Day 6 Day 14 Day 28	0 - 3 -	<1 <1 <1 <1	<5 <5 <5 <5	13800 - 31100 -	12.1 - 71.0 -	scLib1/2, bulkLib3
CD1299 (f)	2.5	1993	2005	Baseline Day 6 Day 14	0 - 1	<1 <1 <1	<5 <5 <5	6000 - 10800	5.0 55.9 23.1	scLib1/2
CD1340 (m)	2.5	1955	2008	Baseline Day 6 Day 14	0 - 1	<1 <1 <1	<5 21 21	8200 - 39900	2.2 169.4 23.4	scLib3
CD1339 (f)	2.5	1954	2009	Baseline Day 6 Day 14	1 - 1	<1 <1 <1	5 8 7	3000 - 8000	3.3 22.9 23.2	scLib3
CD1295 (f)	2.5	1972	2003	Baseline Day 6 Day 14	0 - 3	<1 <1 <1	<5 <5 <5	9200 - 17800	49.5 - 91.4	scLib2
CD1342 (f)	2.5	1988	2005	Baseline Day 6 Day 14	0 - 1	<1 2.4 2.3	<5 5 5	1000 - 5000	1.6 21.0 18.4	scLib3
CD114 (m)	2.5	1965	1969	19.5yr GFD 20yr GFD 47yr GFD	- - 0	- - <1	- - <5	- - 5500	28.0 50.8 11.7	bulkLib4 scLib4/5, bulkLib4
CD412 (f)	2.5	1961	1996	UCD 20yr GFD	- 0	- <1	- <5	TCL 3600	72.0 88.2	scLib4/5, bulkLib4
CD373 (f)	2.5	1967	1995	1yr GFD 2yr GFD 21yr GFD	- - 1	- - <1	- - <5	TCL - 6800	- 4.3 13.2	scLib4 scLib4/5
CD364 (f)	2.5	1950	1991	3yr GFD 9yr GFD 25yr GFD	- - 0	- - <1	- - <5	- TCL 12200	2.4 - 7.4	scLib4 scLib4/5
CD436 (f)	2.5	1953	1996	4yr GFD 20yr GFD	- 0	- <1	- <5	- 2800	25.8 21.1	scLib4 scLib4/5

^a m – male, f – female

^b Gluten status indicates time on a gluten-free diet; untreated celiac disease (UCD) (implicating a gluten-containing diet) or weeks (w) or years (yr) on a gluten-free diet. Gluten status also indicate stage of gluten challenge (Baseline, Day 6, Day 14, Day 28)

^c Celiac disease is diagnosed based on histological appearance in the small intestinal mucosa, which can be graded according to the Marsh score into normal mucosa (Marsh 0), increased intraepithelial lymphocyte number (Marsh 1), hyperplastic lesion and crypt hyperplasia (Marsh 2) and variable degree of villous atrophy (Marsh 3a-c). In some cases, patchy lesions give variations in the histological assessment of different biopsy specimens.

^d Titer of IgA anti-transglutaminase 2 (IgA-TG2) at celiac disease diagnosis. Undetectable titers are shown as <1.

^e Titer of IgG anti-deamidated gliadin peptide (IgG-DGP) at celiac disease diagnosis. Undetectable titers are shown as <5.

^f Number of HLA-DQ:gluten tetramer-binding CD4⁺ T cells per million CD4⁺ T cells in gut biopsy. TCL: T-cell line cultured in vitro from one single duodenal biopsy.

^g Number of HLA-DQ:gluten tetramer-binding effector-memory gut-homing CD4⁺ T cells per million CD4⁺ T cells in blood.

^h T cells were sorted at various time points and prepared and included in multiple TCR sequencing libraries. scLib: single-cell sequencing TCR library, bulkLib: bulk TCR sequencing library

Table S2. List of CDR3 amino acid sequences of public TCR sequences.

AV_CDR3α_AJ	Number of patients	Total number of sequences	Number of sequences															
			CD1375	CD1368	CD1237	CD1268	CD1283	CD114	CD412	CD373	CD364	CD436	CD1300	CD442	CD1299	CD1340	CD1339	CD1295
AV4_LVGDDTGFQKLV_AJ8	13	25	4		2	3	1		1	1	1	2	2	1	3		3	1
AV26-1_IAFNDYKLS_AJ20	9	28		5		4	1	3				4		8	1	1	1	1
AV8-1_AVNARNAGNMLT_AJ39	7	29	1	2		6		5	8			5				2		
AV4_LVGEGLDSNYQLI_AJ33	5	11			2		6	1			1	1						
AV4_LVGGSGGYNKLI_AJ4	5	21			3			4						2	1			11
AV12-3_AMSAGTGNQFY_AJ49	4	7					1			1			3		2	2		
AV14/DV4_AMREGRYSSASKII_AJ3	3	6	4					1	1									
AV19_ALSEAFGAGGTSYGKLT_AJ52	4	8	1			2						2	3					
AV4_LVGGAGGYNKLI_AJ4	5	11		1	6					1	2					1		
AV8-3_AVGAAEYGNKLV_AJ47	4	14								2		7		2		3		
AV41_AVESGSNYQLI_AJ33	4	13	8			1						3		1				
AV12-3_AMSELPGGSNYKLT_AJ53	4	18		9				1				7						1
AV26-1_IVLNARLM_AJ31	4	7						1				2				2	2	
AV26-1_IVYGGSQGNLI_AJ42	3	10			1									8		1		
AV26-1_IVFNDYKLS_AJ20	3	3	1	1										1				
AV19_ALSGAGANSKLT_AJ56	3	4						1						1	2			
AV26-1_IAYNDYKLS_AJ20	3	5						1									1	3
AV26-1_IVRVVGDDKII_AJ30	4	6		1	1					1								3
AV4_LVGDGDGGATNKLI_AJ32	4	5	1					2	1					1				
AV35_IGNYGGATNKLI_AJ32	5	13	4	3					1	1						4		
AV12-3_AMTDYGNRRLA_AJ7	4	5			1	1							1			2		
AV41_AVEGGSNYKLT_AJ53	4	21						2				1			2	16		
AV12-2_AVSNRDDKII_AJ30	4	7			1				3	1							2	
AV19_ALSEAGANSKLT_AJ56	3	8			1							1			6			
AV9-2_ALSEGPNFKFY_AJ21	3	7										1	5				1	
AV12-2_AVPNRDDKII_AJ30	3	4					1		2				1					
AV12-1_VVTLMMDTGRALTAJ5	3	13	11		1								1					
AV26-1_IDPGSSNTGKLI_AJ37	2	4	3											1				
AV35_AGFNTDKLI_AJ34	2	2							1		1							
AV26-1_IPNYGGSGQNLI_AJ42	2	2		1										1				
AV4_LVGGDNQGGKLI_AJ23	2	2		1														
AV19_ALSEGGNQGGKLI_AJ23	3	3	1								1							
AV1-2_AVTSNTGKLI_AJ37	3	6				3									2	1		
AV26-1_IVYNDYKLS_AJ20	3	4		1			1	2										
AV35_AGPYNTDKLI_AJ34	3	3		1					1							1		
AV13-2_AETNAGGTSYGKLT_AJ52	3	3					1	1						1				
AV26-1_IGNYGGSGQNLI_AJ42	3	7						4		1					2			
AV12-3_AMIEAAGNKLTAJ17	3	3											1		1		1	
AV35_AGDSNYQLI_AJ33	3	10						1						1	8			
AV1-2_AVLTDSWGKLQ_AJ24	2	8						1					7					
AV26-1_ISFNDYKLS_AJ20	2	9											4				5	
AV13-2_AEGDAGGTSYGKLT_AJ52	2	4	2										2					
AV12-3_AMIQAAGNKLTAJ17	2	2											1				1	
AV8-3_AVGAVEYGNKLV_AJ47	2	2											1		1			
AV8-3_AVGVSEYGNKLV_AJ47	2	7		1									6					
AV19_ALSEGGFGNVLH_AJ35	2	4	3										1					
AV35_AGQLGGATNKLI_AJ32	2	9						5					4					
AV8-3_AVGLTDSWGKLQ_AJ24	2	3								1			2					
AV4_LVGVMEMYGNKLV_AJ47	2	2	1											1				
AV29/DV5_AASEETSGSRLTAJ58	2	2						1					1					
AV12-3_AMSEIPGGSNYKLT_AJ53	2	3						2					1					
AV35_AGNDYKLS_AJ20	2	4											2				2	
AV38-1_AFTVYTGANSKLT_AJ56	2	4											1		3			

AV8-4/8-2_ASLSNFGNEKLT_AJ48	2	3										1							2	
AV12-3_AMSEGTTGNQFY_AJ49	2	2										1	1	1						
AV9-2_ALSDQTGANNLF_AJ36	2	2						1					1							
AV29/DV5_AASAGETSGSRLT_AJ58	2	8																7		1
AV12-2_ASQDTGRRALT_AJ5	2	13																1		12
AV19_ALSEGGNAGNMLT_AJ39	2	2						1											1	
AV16_ALSDSNYQLI_AJ33	2	3			2														1	
AV35_AVGVYNNNDMR_AJ43	2	3					2												1	
AV26-1_IVYNARLM_AJ31	2	3						2											1	
AV17_ATEGNTGFQKLV_AJ8	2	2		1															1	
AV6_ALPSGYALN_AJ41	2	2							1										1	
AV2_AVEDLRRAGSYQLT_AJ28	2	2			1														1	
AV8-3_AVGVDRGSTLGRLY_AJ18	2	7	6															1		
AV4_LVGGDSSYKLI_AJ12	2	2	1	1																
AV12-2_AVFPGGATNKLI_AJ32	2	3	1																	2
AV14/DV4_AMREEGSQGNLI_AJ42	2	2	1															1		
AV19_ALSGGGANSKLT_AJ56	2	2	1															1		
AV4_LVGDENTGTASKLT_AJ44	2	11				10												1		
AV29/DV5_AATNTNAGKST_AJ27	2	2				1				1										
AV6_ALSTDTSWGKLQ_AJ24	2	3			2	1														
AV16_ALNSGGYQKVT_AJ13	2	15		2					13											
AV29/DV5_AASALTSGTYKYL_AJ40	2	3		2														1		
AV39_AVDPGYALN_AJ41	2	2		1								1								
AV29/DV5_AASEQSGGSNYKLT_AJ53	2	3		2															1	
AV12-3_AMLEAAGNKLTAJ17	2	24								1		23								
AV9-2_ALAEYNFNKFY_AJ21	2	2						1					1							
AV41_AVETSGSRLT_AJ58	2	2				1								1						
AV35_AGQVGSSNTGKLI_AJ37	2	2											1					1		
AV9-2_ALSDPTGTASKLT_AJ44	3	5				2							1				2			
AV12-3_AMRDYGQNFV_AJ26	2	12				3												9		
AV1-2_AVRAVVSGGYNKLIAJ4	2	18			1												17			
AV35_AGDGGGADGLT_AJ45	2	3					2										1			
AV4_LVGLTGGGNKLTAJ10	2	9					8			1									31	
AV9-2_ALSDQDTGRRALT_AJ5	2	32							1											
AV9-2_ALSDGSGAGSYQLT_AJ28	2	11				9			2											
AV22_AVELQGAQKLV_AJ54	2	3					1	2												
AV29/DV5_AASVATDSWGKLQ_AJ24	2	2						1				1		1						
AV2_AVEVYNFNKFY_AJ21	2	3					1	2												
AV8-3_AVATDRGSTLGRLY_AJ18	2	3															1	2		
AV19_ALSEGSNAGNMLT_AJ39	2	4				1											3			
AV29/DV5_AASADAGTSYGKLT_AJ52	2	2															1	1		
AV12-1_VVNSASSASKII_AJ3	2	6			5													1		
AV8-3_AVGLDRGSTLGRLY_AJ18	2	2					1											1		
AV26-1_IVTGNQFY_AJ49	2	4					1											3		
AV8-1_AVNRNTGFQKLV_AJ8	2	6															1		5	
AV4_LVGQNFGNEKLT_AJ48	2	8							2	6										
AV12-3_AMKDYGQNFV_AJ26	2	8								6									2	
AV12-3_AMSEAAGNKLTAJ17	2	4	3							1										
AV17_ATDDKGGEKLV_AJ57	2	3															1			2
AV12-3_AMSASSGGGADGLT_AJ45	2	7					6													1
AV4_LVDNAGNMLT_AJ39	2	4					1										3			
AV1-2_AVRAVFSGGYNKLIAJ4	2	4				3											1			
AV26-1_IVHNARLM_AJ31	2	2						1					1							
AV26-1_IVYNNNDMR_AJ43	2	2					1						1							
AV26-1_IVTDGQKLL_AJ16	2	5											1					4		
AV21_AVGTGYKYL_AJ40	2	2							1			1							1	
AV1-2_AVTSNTGKLI_AJ37	2	2					1					1								
AV8-3_AVGTDRGSTLGRLY_AJ18	2	3		2					1			1					1	34	40	
Total number of sequences			58	33	28	35	29	67	49	11	26	38	76	70	52	34	50	34	40	

Same TCRα																				
				Number of sequences																
		Number of patients	Total number of sequences	CD1375	CD1368	CD1237	CD1268	CD1283	CD114	CD412	CD373	CD364	CD436	CD1300	CD442	CD1299	CD1340	CD1339	CD1295	CD1342
BV7-2_ASSLRSTDTQY_BJ2-3	15	25	1	1	1	1	1	2	1	1	1	1	4		1	4	4	1		
BV7-2_ASSIRSTDTQY_BJ2-3	13	29		3	3	2		3	2	3	1	1	4	1		2	3	1		
BV7-2_ASSVRSTDTQY_BJ2-3	11	33		1	1		1	4	5	1		1	1		1	16		1		
BV7-3_ASSIRSTDTQY_BJ2-3	8	15	4	1	1		1		1		1		5				1			
BV7-2_ASSFRSTDTQY_BJ2-3	10	30		3	1		4	1	3	1		1		9	4		3			
BV7-2_ASSLRAGGADTQY_BJ2-3	6	9	1						1		1	2				3	1			
BV7-2_ASSLRFTDTQY_BJ2-3	7	11		2			2		2			1				2	1	1		
BV7-2_ASSIRATDTQY_BJ2-3	5	8		4			1				1	1		1						
BV15_ATSRAGGGGEKLF_BJ1-4	3	7	4							2							1			
BV7-2_ASSLVGVWETQY_BJ2-5	4	4			1			1	1	1										
BV20-1_SASRQVNTEAF_BJ1-1	4	4				1		1	1							1				
BV7-2_ASSIRHTDTQY_BJ2-3	5	5			1					1				1		1	1			
BV5-1_ASSFDGETQY_BJ2-5	3	12				6		1					5							
BV29-1_SVGGSGANVLT_BJ2-6	4	10				1							3		1		5			
BV7-3_ASSFRSTDTQY_BJ2-3	5	10				1			1				1			6	1			
BV7-3_ASSIRATDTQY_BJ2-3	4	13	7				3					2			1					
BV11-2_ASSSTAQETQY_BJ2-5	3	7				2		4						1						
BV7-2_ASSLRYTDTQY_BJ2-3	4	5		1							1			1			2			
BV9_ASSVGGGAGDTQY_BJ2-3	4	9			3						1	4					1			
BV4-3/4-2_ASSQGSGGNEQF_BJ2-1	4	5	1					2	1					1						
BV4-3/4-2_ASSQGLAGRQETQY_BJ2-5	4	6		2		1					2			1						
BV7-2_ASSLRATDTQY_BJ2-3	4	6			1				2	1						2				
BV7-2_ASSLRHTDTQY_BJ2-3	3	12									2	8					2			
BV7-3_ASSQQDTEAF_BJ1-1	3	3		1								1					1			
BV19_ASSIRTGGSEQY_BJ2-7	3	12											3	1	8					
BV7-6_ASSFGSYNEQF_BJ2-1	3	3		1								1	1							
BV29-1_SVGAVENTDTQY_BJ2-3	3	5								1		3			1					
BV30_AWSVTGWDTGELF_BJ2-2	3	4								2		1		1						
BV5-1_ASSLGGGAGDTQY_BJ2-3	3	3										1			1		1			
BV7-2_ASSFRYTDTQY_BJ2-3	2	2		1					1											
BV7-2_ASSYRSTDTQY_BJ2-3	2	2	1														1			
BV7-3_ASSLRATDTQY_BJ2-3	2	2					1										1			
BV7-2_ASSLRAGGGDTQY_BJ2-3	2	4		3													1			
BV7-2_ASSFRHTDTQY_BJ2-3	2	2			1				1											
BV7-2_ASSIRYTDTQY_BJ2-3	2	3		2							1				33		1			
BV7-2_ASSIRFTDTQY_BJ2-3	3	36								2										
BV7-3_ASSLRSTDTQY_BJ2-3	3	3						1							1		1			
BV7-2_ASSVRFTDTQY_BJ2-3	3	11			1			2	8											
BV7-6_ASSLAGFDSPHL_BJ1-6	3	8	3								4						1			
BV20-1_SARVWNTEAF_BJ1-1	3	5	2						1	2										
BV5-6/5-5_ASSFGVTGELF_BJ2-2	3	3	1				1	1												
BV7-6_ASSLASAGGTDTQY_BJ2-3	3	3	1						1						1					
BV29-1_SGGQGETQY_BJ2-5	3	3	1												1	1				
BV29-1_SVGAGGTGELF_BJ2-2	3	20					2									15		3		
BV5-1_ASSLGQPSTDQY_BJ2-3	2	2	1										1							
BV5-6/5-5_ASSFGPSNQPQH_BJ1-5	2	10											9		1					
BV18_ASSPAGWDTEAF_BJ1-1	2	2					1						1							
BV12-3/12-4_ASRLTLGTDQY_BJ2-3	2	2	1										1							
BV29-1_SAGQGGTGEFL_BJ2-2	2	4						1					3							
BV4-1_ASSLSDSDQPQH_BJ1-5	2	2											1	1						

Same TCR β

Shared with one TCR α

Shared with two TCRα

Shared with three TCR α

Table S3. List of CDR3 nucleotide sequences of paired public TCR sequences.

Sequence ID	Donor ID	Time-point	Source	Sequencing library	CDR3 α (nt)*	CDR3 β (nt)*
AV4_LVGDGDGGATNKL_AJ32 : BV4-2_ASSQGSGGNEQF_BJ2-1	CD1283	UCD	PBMC	lib4	ctcggtggtgacggaaatgggtgtctacaacaagctcatc	gccaggccaaagg <u>gacgggg</u> aatggcgttc
	CD1283	2 yr GFD	PBMC	lib6	ctcggtggtgacggaaatgggtgtctacaacaagctcatc	gccaggccaaagg <u>atccgggg</u> aatggcgttc
	CD114	20 yr GFD	PBMC	lib5	ctcggtggtgacggaaatgggtgtctacaacaagctcatc	gccaggccaaagg <u>ctccgggg</u> aatggcgttc
	CD1299	Day 14	Gut	lib2	ctcggtggtgacggaaatgggtgtctacaacaagctcatc	gccaggccaaagg <u>gactgggg</u> aatggcgttc
	CD1375	4 wk GFD	PBMC	lib4	ctcggtggtgacggaaatgggtgtctacaacaagctcatc	gccaggccaaagg <u>gacgggg</u> aatggcgttc
AV12-3_AMSAGTGNQFY_AJ49 : BV29-1_SVGAVSTDQY_BJ2-3	CD1340	Day 14	PBMC	lib3	gcaatggcgcc <u>agg</u> accggtaaccagtctat	agcgttgg <u>ggcg</u> atggcgttc
	CD1300	Day 14	PBMC	lib1	gcaatggcgcc <u>ggg</u> accggtaaccagtctat	agcgttgg <u>ggcg</u> atggcgttc
	CD1300	Day 6	PBMC	lib1	gcaatggcgcc <u>ggg</u> accggtaaccagtctat	agcgttgg <u>ggcg</u> atggcgttc
	CD364	25 yr GFD	Gut	lib4	gcaatggcgcc <u>ggg</u> accggtaaccagtctat	agcgttgg <u>ggcg</u> atggcgttc
AV8-1_AVNARNAGNMLT_AJ39 : BV5-1_ASSFDGETQY_BJ2-5	CD114	20 yr GFD	PBMC	lib4	gcgtgaatgc <u>aag</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1268	1 year GFD	Gut	lib4	gcgtgaatgc <u>acg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1268	1 year GFD	Gut	lib4	gcgtgaatgc <u>acg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1268	1 year GFD	PBMC	lib4	gcgtgaatgc <u>acg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1268	2 yr GFD	Gut	lib6	gcgtgaatgc <u>acg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1268	UCD	PBMC	lib4	gcgtgaatgc <u>acg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1268	UCD	PBMC	lib4	gcgtgaatgc <u>acg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1300	Baseline	PBMC	lib1	gcgtgaatgc <u>ccg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1300	Day 14	PBMC	lib1	gcgtgaatgc <u>ccg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1300	Day 28	PBMC	lib6	gcgtgaatgc <u>ccg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1300	Day 6	PBMC	lib1	gcgtgaatgc <u>ccg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
	CD1300	Day 6	PBMC	lib1	gcgtgaatgc <u>ccg</u> aatgcggccaatgcgtacc	gccaggcc <u>tcc</u> atggagagaccgtac
AV41_AVEGGSNYQLI_AJ33 : BV29-1_SVGGSGANVLT_BJ2-6	CD1300	Day 6	PBMC	lib1	gctgtga <u>atcg</u> ggggagcaactatcgatatac	agcgttgg <u>gggg</u> tccggggccaacgtccgtact
	CD1300	Day 6	PBMC	lib1	gctgtga <u>atcg</u> ggggagcaactatcgatatac	agcgttgg <u>gggg</u> tccggggccaacgtccgtact
	CD1268	2 yr GFD	PBMC	lib6	gctgtga <u>gat</u> ttgtacaactatcgatatac	agcgttgg <u>gggg</u> tccggggccaacgtccgtact
	CD1340	Day 14	Gut	lib3	gctgtga <u>gtcc</u> gggtacaactatcgatatac	agcgttgg <u>gggg</u> tccggggccaacgtccgtact
AV26-1_IAFDNYKLS_AJ20 : BV7-2_ASSLRSTDQY_BJ2-3	CD1300	Day 14	Gut	lib2	atcg <u>cctt</u> caacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1300	Day 6	PBMC	lib1	atcg <u>cctt</u> caacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1342	Day 6	PBMC	lib3	atcg <u>cctt</u> caacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD412	20 yr GFD	PBMC	lib4	atcg <u>cctt</u> caacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
AV4_LVGGSGGYNKL_AJ4 : BV11-2_ASSSTAQETQY_BJ2-5	CD1299	Day 14	PBMC	lib2	ctcggtgg <u>ttc</u> atgggtgtctacaataagctatt	gccaggcc <u>tcc</u> atggagacaccgtat
	CD412	20 yr GFD	PBMC	lib5	ctcggtgg <u>ttc</u> atgggtgtctacaataagctatt	gccaggcc <u>tcc</u> acacggcc <u>ca</u> agagaccgtat
	CD1268	UCD	PBMC	lib4	ctcggtgg <u>ttc</u> atgggtgtctacaataagctatt	gccaggcc <u>tcc</u> acacggcc <u>ca</u> agagaccgtat
	CD1268	1 year GFD	Gut	lib4	ctcggtgg <u>ttc</u> atgggtgtctacaataagctatt	gccaggcc <u>tcc</u> acacggcc <u>ca</u> agagaccgtat
AV35_AGPYNTDKLI_AJ34 : BV7-6_ASSLASAGGTDQY_BJ2-3	CD1340	Baseline	Gut	lib3	gctgg <u>cc</u> tataaacccgacaagctcatc	gccaggcc <u>tcc</u> atggggggcacagatacgcatat
	CD1368	16 wk GFD	PBMC	lib4	gctgg <u>cc</u> tataaacccgacaagctcatc	gccaggcc <u>tcc</u> atggggggcacagatacgcatat
	CD412	20 yr GFD	PBMC	lib4	gctgg <u>cc</u> tataaacccgacaagctcatc	gccaggcc <u>tcc</u> atggggggcacagatacgcatat
AV26-1_IAFDNYKLS_AJ20 : BV7-2_ASSFRSTDQY_BJ2-3	CD412	20 yr GFD	PBMC	lib4	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD412	20 yr GFD	PBMC	lib4	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1299	Day 14	Gut	lib2	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1299	Day 14	Gut	lib2	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1299	Day 14	Gut	lib2	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1299	Day 14	Gut	lib2	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1299	Day 14	Gut	lib2	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1299	Baseline	PBMC	lib1	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1283	1 year GFD	PBMC	lib4	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1283	UCD	PBMC	lib4	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1283	1 year GFD	PBMC	lib4	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
	CD1283	2 yr GFD	PBMC	lib6	atcg <u>cattt</u> aaacgactacaagctcgc	gccaggcc <u>tcc</u> atggagacaccgtat
AV35_AGQLGGATNKL_AJ32 : BV5-1_ASSLVAWDTEAF_BJ1-1	CD1300	Day 14	Gut	lib2	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
	CD1300	Day 14	Gut	lib2	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
	CD1300	Day 14	Gut	lib2	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
	CD1300	Day 14	Gut	lib2	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
	CD1283	1 year GFD	PBMC	lib4	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
	CD1283	UCD	PBMC	lib4	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
	CD1283	UCD	PBMC	lib4	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
	CD1283	2 yr GFD	PBMC	lib6	gctgg <u>ca</u> ttttgtgggtctacaataacaagctcatc	gccaggcc <u>tcc</u> atggggacactgaagcttc
AV12-3_AMSAGTGNQFY_AJ49 : BV29-1_SVGLVSTDQY_BJ2-3	CD114	20 yr GFD	PBMC	lib4	gcaatggcgcc <u>agg</u> accggtaaccagtctat	agcgt <u>ccg</u> actatcgacaccgtat
	CD1300	Baseline	PBMC	lib1	gcaatggcgcc <u>ggg</u> accggtaaccagtctat	agcgt <u>ccg</u> actatcgacaccgtat
AV8-3_AVGAVEYGNKL_AJ47 : BV30_AWSVTGWDTGEFL_BJ2-2	CD1300	Day 6	PBMC	lib1	gctgtgggtcggtggataatggaaacaa <u>actggc</u> t	gcctgg <u>gggt</u> at <u>ac</u> gggtggggacaccggggagctgtt
	CD1299	Day 14	PBMC	lib2	gctgtgggtcggtggataatggaaacaa <u>actggc</u> t	gcctgg <u>gggt</u> at <u>ac</u> gggtggggacaccggggagctgtt

AV26-1_IVYNDYKLS_AJ20: BV7-2_ASSLRSTDQY_BJ2-3	CD114	20 yr GFD	PBMC	lib5	atcg tta aacgactacaagctcgc	gccagg cgtt aa gg gacacatacgc cat
	CD114	20 yr GFD	PBMC	lib4	atcg tta aacgactacaagctcgc	gccagg cgtt aa gg gacacatacgc cat
	CD1283	1 year GFD	PBMC	lib4	atcg tta aacgactacaagctcgc	gccagg cgtt aa gg gacacatacgc cat
AV2_AVEVYNFKFY_AJ21: BV29-1_SVAESSNSPLH_BJ1-6	CD114	47 yr GFD	PBMC	lib4	gctgtggagg tt tatacaacttcacaaaattttac	agcgttg cgg ca gg gactcaattcacccctccac
	CD412	20 yr GFD	PBMC	lib4	gctgtggagg tt tatacaacttcacaaaattttac	agcgttg cgg ca gg gactcaattcacccctccac
	CD412	20 yr GFD	PBMC	lib4	gctgtggagg tt tatacaacttcacaaaattttac	agcgttg cgg ca gg gactcaattcacccctccac
AV29/DV5_AASVATDSWGKLQ_AJ24: BV10-3_AISASGTEAF_BJ1-1	CD364	25 yr GFD	PBMC	lib4	gcaga gg gt gg ca gg actgcac gg ctggggaaattgcag	gccccatcg tt cc gg act gg ttcc
	CD412	20 yr GFD	PBMC	lib4	gcaga gg gt gg ca gg actgcac gg ctggggaaattgcag	gccccatcg tt cc gg act gg ttcc
	CD364	25 yr GFD	Gut	lib4	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	20 yr GFD	PBMC	lib5	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	20 yr GFD	PBMC	lib5	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	20 yr GFD	PBMC	lib5	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
AV4_LVGTLGGGNKLT_AJ10: BV29-1_SVEDQSGEKLF_BJ1-4	CD412	UCD	PBMC	lib4	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	20 yr GFD	PBMC	lib4	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	20 yr GFD	PBMC	lib4	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	20 yr GFD	PBMC	lib4	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	UCD	PBMC	lib4	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	UCD	Gut	lib4	ctcg ggg ta cc tcac ggg agg ggg aaaaactcacc	agcgttg gg aa gg gat gg ttccaaaaactgttt
	CD412	20 yr GFD	PBMC	lib4	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	20 yr GFD	PBMC	lib5	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	47 yr GFD	PBMC	lib5	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	47 yr GFD	PBMC	lib5	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
AV9-2_ALSDGSGAGSYQLT_AJ28: BV24-1_ATSDFQGNYGYT_BJ1-2	CD114	47 yr GFD	PBMC	lib5	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	20 yr GFD	PBMC	lib4	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	47 yr GFD	PBMC	lib4	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	47 yr GFD	PBMC	lib4	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	20 yr GFD	PBMC	lib4	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
	CD114	47 yr GFD	PBMC	lib4	gctctg gg at gg ct ggg ct ggg gttaccaactcact	gcccaccagtgttcc ggg aa ct at gg ctacacc
AV19_ALSEGNGQGGKLI_AJ23: BV5-5_ASSLRQLYEQY_BJ2-7	CD1340	Baseline	Gut	lib3	gctctg gg at gg gt gg ta cc acc ggg agg ggg aaaaacttac	gcccagg cgtt cc gg ac gg ct cc ac gg act gg
	CD373	21 yr GFD	PBMC	lib4	gctctg gg at gg gt gg ta cc acc ggg agg ggg aaaaacttac	gcccagg cgtt cc gg ac gg ct cc ac gg act gg
AV12-3_AMIEAAGNKL_AJ17: BV5-1_ASSLGGGAGDTQY_BJ2-3	CD1342	Baseline	Gut	lib3	gcaat gt cg gg act gg ca gg ca gg act gg act	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
	CD1340	Baseline	Gut	lib3	gcaat gt cg gg act gg ca gg ca gg act gg act	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
	CD1339	Day 6	PBMC	lib3	atcg tat tg ggg ga gg cca gg agg gg aaat tc cat	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
	CD1339	Day 14	Gut	lib3	atcg tat tg ggg ga gg cca gg agg gg aaat tc cat	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
AV26-1_IVYGGSQGNLI_AJ42: BV7-3_ASSFRSTDQY_BJ2-3	CD1339	Day 14	Gut	lib3	atcg tat tg ggg ga gg cca gg agg gg aaat tc cat	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
	CD1339	Day 6	PBMC	lib3	atcg tat tg ggg ga gg cca gg agg gg aaat tc cat	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
	CD1339	Day 14	Gut	lib3	atcg tat tg ggg ga gg cca gg agg gg aaat tc cat	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
	CD1342	Day 14	Gut	lib3	atcg tat tg ggg ga gg cca gg agg gg aaat tc cat	gcccagg cgtt cc gg gg gg gg gg cc gg gata gg ct gg
AV12-3_AMTDYGNRNL_AJ7: BV5-1_ASSLGGPNTGELF_BJ2-2	CD442	Day 6	PBMC	lib3	gcaat gccc act ggg ga gg aca gg aca gg act gg ct	gcccagg cgtt cc gg gg gg cc gg ac gg cc gg gg gg gat gg ct gg
	CD1339	Day 14	Gut	lib3	gcaat gccc act ggg ga gg aca gg aca gg act gg ct	gcccagg cgtt cc gg gg gg cc gg ac gg cc gg gg gg gat gg ct gg
AV26-1_IWTGNQFY_AJ49: BV7-2_ASSIRSTDQY_BJ2-3	CD1339	Baseline	Gut	lib3	atcg tat cc gg gg gg cc gg gg gg act gg ct	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD114	47 yr GFD	PBMC	lib4	atcg tat cc gg gg gg cc gg gg gg act gg ct	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
AV12-3_AMSEAAGNKL_AJ17: BV9_ASSVGGAGDTQY_BJ2-3	CD1237	UCD	PBMC	lib2	gcaat gccc act ggg ca gg aca gg aca gg act gg ct	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD1237	UCD	PBMC	lib2	gcaat gccc act ggg ca gg aca gg aca gg act gg ct	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD1237	UCD	PBMC	lib2	gcaat gccc act ggg ca gg aca gg aca gg act gg ct	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	25 yr GFD	PBMC	lib4	gcaat gccc act ggg ca gg aca gg aca gg act gg ct	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
AV12-3_AMKDYGQNFS_AJ26: BV7-8_ASSFDNSPLH_BJ1-6	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at ttt tt ttt tc	gcccagg cgtt cc gg gg gg cc gg gg gg act gg ct
	CD364	9 yr GFD	Gut	lib5	gcaat gaaa act ttt gt ttt ca ttt at<	

AV26-1_IAYNDYKLS_AJ20: BV7-2_ASSFRSTDYTQY_BJ2-3	CD1342	Day 6	PBMC	lib3	atcg <u>cctata</u> acgactacaagctcagc	gccagcagct <u>ta</u> gaagcacagatacgcgtat
	CD1342	Day 6	PBMC	lib3	atcg <u>cctata</u> acgactacaagctcagc	gccagcagct <u>ta</u> gaagcacagatacgcgtat
	CD1342	Day 6	PBMC	lib3	atcg <u>cctata</u> acgactacaagctcagc	gccagcagct <u>ta</u> gaagcacagatacgcgtat
	CD114	20 yr GFD	PBMC	lib4	atcg <u>cctata</u> acgactacaagctcagc	gccagcagct <u>c</u> gaagcacagatacgcgtat

* The non-germline encoded nucleotides are underlined. Due to uncertainties in D-segment assignment, all the nucleotide that are non-germline encoded in V or J are underlined. The different nucleotides that encode same amino acids are shown in red.